New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
08:38 EDTAVNRAvanir to present data related to safety and efficacy of AVP-825
Avanir Pharmaceuticals announced that data related to the safety and efficacy of AVP-825, a Breath-Powered Nasal Delivery of Powdered Sumatriptan for the acute treatment of migraine, will be presented at the American Headache Society's 56th Annual Scientific Meeting. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath-Powered delivery technology.
News For AVNR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 11, 2014
08:28 EDTAVNRAvanir added to SMID-Cap Alpha List at BofA/Merrill
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use